These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

533 related items for PubMed ID: 11941943

  • 1. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
    Wang WS, Lin JK, Chiou TJ, Liu JH, Fan FS, Yen CC, Lin TC, Jiang JK, Yang SH, Wang HS, Chen PM.
    Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
    [Abstract] [Full Text] [Related]

  • 2. Factors predictive of survival in patients with node-positive colorectal cancer in Taiwan.
    Wang WS, Chen PM, Chiou TJ, Liu JH, Fan FS, Lin TC, Jiang JK, Yang SH, Yen CC, Wang HS, Lin JK.
    Hepatogastroenterology; 2000; 47(36):1590-4. PubMed ID: 11149009
    [Abstract] [Full Text] [Related]

  • 3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Lamerz R.
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [Abstract] [Full Text] [Related]

  • 4. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
    Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K.
    Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
    [Abstract] [Full Text] [Related]

  • 5. Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.
    Sasaki A, Kawano K, Inomata M, Shibata K, Matsumoto T, Kitano S.
    Hepatogastroenterology; 2005; 52(66):1814-9. PubMed ID: 16334783
    [Abstract] [Full Text] [Related]

  • 6. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC.
    J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
    [Abstract] [Full Text] [Related]

  • 7. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
    Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Pahl H, Fateh-Moghadam A.
    Anticancer Res; 1997 Apr; 17(4B):2935-8. PubMed ID: 9329568
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma.
    Diez M, Cerdán FJ, Pollán M, Maestro ML, Ortega MD, Martínez S, Moreno G, Balibrea JL.
    Anticancer Res; 1994 Apr; 14(6B):2819-25. PubMed ID: 7872725
    [Abstract] [Full Text] [Related]

  • 9. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L, Castoldi R, Di Palo S, Arru M, Stella M, Orsenigo E, Gavazzi F, Ferla G, Di Carlo V, Staudacher C.
    Chir Ital; 2005 Apr; 57(5):555-70. PubMed ID: 16241086
    [Abstract] [Full Text] [Related]

  • 10. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer.
    Iizasa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shibuya K, Hiroshima K, Nakatani Y, Fujisawa T.
    Ann Thorac Surg; 2006 Jul; 82(1):254-60. PubMed ID: 16798225
    [Abstract] [Full Text] [Related]

  • 11. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP.
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [Abstract] [Full Text] [Related]

  • 12. The prognostic value of preoperative serum levels of CEA and CA19-9 in patients with gastric cancer.
    Kodera Y, Yamamura Y, Torii A, Uesaka K, Hirai T, Yasui K, Morimoto T, Kato T, Kito T.
    Am J Gastroenterol; 1996 Jan; 91(1):49-53. PubMed ID: 8561143
    [Abstract] [Full Text] [Related]

  • 13. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
    Pfannschmidt J, Bade S, Hoheisel J, Muley T, Dienemann H, Herpel E.
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
    [Abstract] [Full Text] [Related]

  • 14. The use of tumor markers as predictors of prognosis in gastric cancer.
    Mihmanli M, Dilege E, Demir U, Coskun H, Eroglu T, Uysalol MD.
    Hepatogastroenterology; 2004 Oct; 51(59):1544-7. PubMed ID: 15362797
    [Abstract] [Full Text] [Related]

  • 15. Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer.
    Gasser M, Gerstlauer C, Grimm M, Bueter M, Lebedeva T, Lutz J, Maeder U, Ribas C, Ribas C, Nichiporuk E, Thalheimer A, Heemann U, Thiede A, Meyer D, Waaga-Gasser AM.
    Ann Surg Oncol; 2007 Apr; 14(4):1272-84. PubMed ID: 17211733
    [Abstract] [Full Text] [Related]

  • 16. Metastatic potential in T1 and T2 colorectal cancer.
    Fang WL, Chang SC, Lin JK, Wang HS, Yang SH, Jiang JK, Chen WC, Lin TC.
    Hepatogastroenterology; 2005 Apr; 52(66):1688-91. PubMed ID: 16334758
    [Abstract] [Full Text] [Related]

  • 17. Carcinoembryonic antigen and CA19-9: implications of quantitative marker measurement in tissues for prognosis of colorectal cancer.
    Gebauer G, Müller-Ruchholtz W.
    Cancer Detect Prev; 2001 Apr; 25(4):344-51. PubMed ID: 11531011
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
    Park IJ, Choi GS, Jun SH.
    Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
    [Abstract] [Full Text] [Related]

  • 19. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
    Zhao XW, Jiang B, Han CZ, Jing JX.
    Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
    [Abstract] [Full Text] [Related]

  • 20. Liver metastasis of colorectal cancer by protein-tyrosine phosphatase type 4A, 3 (PRL-3) is mediated through lymph node metastasis and elevated serum tumor markers such as CEA and CA19-9.
    Hatate K, Yamashita K, Hirai K, Kumamoto H, Sato T, Ozawa H, Nakamura T, Onozato W, Kokuba Y, Ihara A, Watanabe M.
    Oncol Rep; 2008 Oct; 20(4):737-43. PubMed ID: 18813812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.